Kornimate/medical-research-clean huggingface dataset:
detecting abnormal blood clotting in patients with metastatic cancer undergoing surgery

Conditions: Thromboembolism; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: a test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. purpose: this laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.

objectives: primary * determine whether whole blood thrombin generation assay (wbtga) detects hypercoagulability in patients with metastatic carcinoma compared with a healthy control group. * determine whether results of the wbtga will change as a result of major surgery performed on patients with metastatic carcinoma. * establish a reference interval for the wbtga using healthy controls. secondary * compare a battery of plasma components known to affect or reflect coagulant or fibrinolytic reactions in patients with metastatic carcinoma vs healthy controls. * establish reference intervals for this battery of tests using healthy controls. * determine how major surgery in cancer patients affects this battery of factors. * identify changes in these factors that correlate with changes in the wbtga. * compare the results of wbtga tests in patients who develop venous thromboembolism (vte) with those who do not. outline: this is a pilot study. blood samples of patients are collected on day -7 and day 1 after surgery. blood samples of healthy controls are collected once. after collection, blood samples are analyzed for hypercoagulability by whole blood thrombin generation assay. routine blood tests are performed, as are immunoenzyme techniques for antigenic tissue plasminogen activator and its inhibitor, thrombin-antithrombin complexes, tissue factor, factor viia, d-dimer, and glycocalicin. projected accrual: a total of 30 patients and 30 healthy controls will be accrued for this study.

Eligibility criteria:
disease characteristics: * patients meeting the following criteria: * diagnosis of metastatic carcinoma * must be enrolled in 1 of the following surgical protocols: * nci-99-c-0123 * nci-00-c-0069 * nci-03-c-0085 * nci-03-c-0212 * healthy control participant\* meeting the following criteria: * no anemia or thrombocytopenia * no history of venous thromboembolism (deep vein thrombosis, pulmonary emboli) * no history of coronary artery disease or stroke * no chronic inflammatory disease * no diabetes mellitus * have not smoked tobacco within the past 6 months note: \* selected on the basis of gender and age to match the patients as they are accrued patient characteristics: * no symptomatic infections or other acute illness within the past 14 days prior concurrent therapy: * at least 3 days since prior drugs known to inhibit platelet function * at least 7 days since prior acetylsalicylic acid * no concurrent estrogen contraceptives or hormone replacement therapy * no concurrent anticoagulants

Keywords: thromboembolism unspecified adult solid tumor, protocol specific
predictive value of human microbiome and serological markers for clinical outcome of ais with active cancer

Conditions: Ischemic Stroke, Acute; Tumor Progression

Summary: explore with active cancer patients with acute ischemic stroke in the human body characteristic microorganism disorder to clinical prognosis of the predictive value of the secondary objective: to observe with active cancer patients with acute ischemic stroke in the body of microorganisms and their serological indexes change law of exploration condition change related biomarkers of microscopic objects group based on the human body.

investigators recently found that changes in gut microbiota in patients with ischemic stroke are associated with the development of disease. however, there are few studies on the correlation between ischemic stroke with cancer and human microbiome and metabolites whether the human microbiome and its metabolites are associated with the prognosis of such patients remains to be investigated. therefore, this study hypothesized that structural changes in the human microbiome and its metabolites in patients with acute ischemic stroke with active cancer were associated with stroke severity and disease recovery therefore, this topic proposed by collecting active follow-up cancer of acute ischemic stroke patients after admission and oral swabs excrement and urine and blood samples, and based on the queue, follow-up analysis of the human microbiome dynamic change rule and the prognosis of patients with cancer of the acute ischemic stroke correlation, activity, further explore the secondary prevention of stroke management strategy based on the human microbiome.

Eligibility criteria:
inclusion criteria: * 1: it meets the diagnostic criteria for acute ischemic stroke 2: age ≥ 18 years 3: the onset time is less than or equal to 2 weeks 4: diagnosis of cancer before stroke onset or during hospitalization and active cancer (failure to meet clinical criteria for cure, or discovery of recurrence or metastasis) 5: sign an informed consent form, provide relevant medical history information and provide biological specimens exclusion criteria: * 1: previous history of disabling stroke (pre-onset mrs ≥2) 2: primary central nervous system tumor or hematologic system tumor 3: the cancer meets the criteria for clinical cure and has not recurred or metastasized for more than 5 years 4: antibiotics, prebiotics/probiotics taken within 1 month 5: patients who cannot have stool specimens within 4 days of admission
study evaluating the safety of enbrel (etanercept)

Conditions: Arthritis, Psoriatic

Summary: the purpose of this study is to collect post-marketing information on the safety of enbrel in filipino patients.


Eligibility criteria:
inclusion criteria: * all patients from the study center who received or will receive at least one dose of enbrel according to the approved product indication. exclusion criteria: * previously discontinued enbrel therapy due to significant safety concern.

Keywords: arthritis psoriatic
the safety evaluation of silver alginate (algidex™) dressing in very low birth weight (vlbw) infants

Conditions: Prematurity; Very Low Birth Weight

Summary: the purpose of this study is to test the safety of silver alginate (algidex™) dressing in vlbw infants in preparation for a large efficacy trial.

we are conducting a pilot randomized controlled trial in vlbw infants to evaluate the safety of silver alginate (algidex™) dressing compared to standard catheter care. following parental consent, infants are randomized to receive silver alginate or standard of care dressing. infants with birth weights less than 1,500 grams admitted to baylor university medical center (bumc) nicu with any of the following lines are eligible for inclusion into this study up to 72 hours after birth: umbilical arterial line (ual), umbilical venous line (uvl), peripheral arterial line (pal), peripheral long line (pll), and central venous line (cvl). safety is assessed by measuring silver levels and monitoring for cutaneous reactions. dressings are changed every seven days. silver levels are drawn on study days 1, 7, and 28. blood culture results are used to compare infection rates between the two groups. patient demographics and clinical conditions are recorded. results will be analyzed based on intention to treat.

Eligibility criteria:
inclusion criteria: * infants with birth weights less than 1,500 grams admitted to baylor university medical center (bumc) nicu with any of the following lines are eligible for inclusion into this study up to 72 hours after birth: umbilical arterial line (ual), umbilical venous line (uvl), peripheral arterial line (pal), peripheral long line (pll), and central venous line (cvl). exclusion criteria: * n/a

Keywords: neonate central lines very low birth weight silver alginate
comparative real world effectiveness of sq sublingual immunotherapy (slit)-tablets vs. controls in allergic rhinitis and asthma

Conditions: Allergy; Allergic Rhinitis; Asthma

Summary: to assess the impact of sq slit-tablets (sq grass slit-tablet and sq hdm slit-tablet) in danish and swedish allergic rhinitis (ar) patients, with or without asthma, between 2007-2020.

allergic rhinitis (ar) is an inflammatory disorder, characterised by pruritus, sneezing, rhinorrhoea, and nasal congestion. it is one of the most common disorders worldwide, with an estimated global prevalence of 10-30%. ar is a chronic and progressive disease, as the underlying respiratory allergy can progress into allergic asthma. the prevalence of asthma in patients with ar is high and estimated between 10-40%. the presence of ar commonly exacerbates asthma, increasing the risk of asthma exacerbations, emergency visits and hospitalisations for asthma. recently, the high-quality retrospective cohort react study (clinicaltrial.gov: nct04125888) found that allergy immunotherapy (ait) was associated with long-term reduction in ar medication use as well as significant reductions in both controller and reliever asthma medication and concurrent lower risk of asthma exacerbation and pneumonia in subjects with pre-existing asthma. the sq sublingual immunotherapy (slit)-tablets have robust evidence from randomised controlled trials (rcts), but real-world evidence (rwe) is needed to complement the findings from rcts by looking at e.g. longer time horizons and broader patient populations. as the react study was not designed to specifically look at evidence-based ait treatments like the sq slit-tablets, the real-world effectiveness of sq slit tablets remain to be further elucidated.

Eligibility criteria:
inclusion criteria: ar-patients identified by dispensations of prescribed ar medications and/or icd10-codes of ar in specialty care for the sq slit-tablet cohort: - at least 2 dispensings within 365 days of sq slit-tablets (atc: v01aa02 and v01aa03) for the control cohort: - unexposed subjects will be identified from the study population of ar-patients that may be eligible to receive sq slit-tablets, but have not dispensed a prescription of sq slit-tablets during the index year of the case or prior to that year exclusion criteria: - allergy immunotherapy treatment with grass or hdm allergens prior to the index event

Keywords: allergy immunotherapy sublingual immunotherapy (slit)-tablets grass house dust mite retrospective cohort study
the ct-based deep learning model predicts complications in partial nephrectomy

Conditions: Renal Cell Carcinoma (RCC); Renal Cyst

Summary: the investigators combine radiomics and deep learning to analyze the lesions more thoroughly, aiming for a more accurate prediction of complications in partial nephrectomy, and compare this approach with traditional models.

in this study, patients diagnosed with renal cell carcinoma or renal cyst who underwent partial nephrectomy across multiple centers was included. and the participants were excluded if they had (a) missing or unavailable imaging data or (b) no available enhanced ct images. the cohort was divided into training and test sets at a 7:3 ratio. after that, the radiomics features were extracted from the images, and lasso regression was used to select features. then a deep learning model was developed to predict complications and risk grades and compared with traditional classification models (renal and padua), demonstrating superior applicability.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of renal cell carcinoma or renal cyst * underwent partial nephrectomy between june 2014 and july 2024 exclusion criteria: * missing or unavailable imaging data * no available enhanced ct images

Keywords: ct-based deep learning complication prediction traditional classification model partial nephrectomy
effect of monosaccharides on intestinal barrier function

Conditions: Dietary Habits; Endotoxemia

Summary: the aim of the present study is to determine the effect of monosaccharides on intestinal barrier function in healthy subjects.

in the intervention study normal weight participants will receive defined amounts of monosaccharides for several days. before and after intervention parameters of intestinal barrier function will be assessed.

Eligibility criteria:
inclusion criteria: * bmi \<25 kg/m2 * no kown history of metabolic disorders or fatty liver exclusion criteria: * food allergies or intolerances (esp. fructose intolerance and malabsorption) * renal insufficiency * chronic disease of the gastrointestinal tract * taking drugs affecting lipid or glucose metabolism
vegetarian diet and chronic degenerative diseases

Conditions: Dementia; Depression; Cardiovascular Diseases; Stroke; Gout; Cataract; Gallstone; Urinary Tract Infections

Summary: to investigate the prospective association between a vegetarian diet and chronic degenerative diseases in two cohorts of taiwanese buddhists

the tzu chi vegetarian study (tcvs) recruited 12062 community volunteers of the buddhists tzu chi foundation throughout taiwan in the year 2005. all participants completed a self-administered questionnaire on basic information, medical history, lifestyle, and diet. the tzu chi health study (tchs) recruited 6002 participants who came to the buddhist tzu chi dalin general hospital for health examination. all participants were interviewed on basic information, medical history, lifestyle, and diet. biochemical and anthropometric data was collected through a health examination: biochemical variables: cbc, fasting glucose, lipid profile (tch, ldl, hdl, tg), bun, cr, alt, ast, and ua. in addition, homocysteine, serum vitamin b12, folate, and c-reactive protein (crp) are available for 1500 subjects. blood: extra blood samples have been obtained and stored for 3500 subjects and will be available for future investigation. anthropometric variables: body weight, height, waist circumference, % body fat (with bia), blood pressure, pulse wave velocity, bone mineral density through dxa (at spine for female and hip for male), lung function test (spirometric), abdominal sonography, colonoscopy, esophageal-gastro-duodenal-scopy, chest x-ray, kub. follow-up: individual baseline data were linked to the national health insurance database and the national death registry to ascertain disease outcomes at the health and welfare data science center.

Eligibility criteria:
inclusion criteria: * participants who consent to be followed. exclusion criteria: * participants with inaccurate id which make linkage to nhird impossible. * participants already with study outcome (disease) prior to enrollment in the study. * participants with missing covariates

Keywords: diet, vegetarian dementia depression cardiovascular diseases stroke gout cataract gallstone urinary tract infections
factors affecting caloric regulation in human feeding

Conditions: Obesity

Summary: this study will test the hypothesis that reducing the energy density of the diet by incorporating more water-rich foods will result in: 1) greater weight loss and weight maintenance; 2) greater diet satisfaction and satiety; and 3) more healthful dietary patterns than reducing dietary fat alone.

energy density refers to the amount of calories (energy) in a given weight of food. for the same amount of energy, a larger volume (weight) of food can be consumed if the food or diet is low in energy density than if the food or diet is high in energy density. the two nutrients that have the largest impact on energy density are fat and water. foods high in fat and low in water content are typically high in energy density, whereas foods low in fat and high in water content, such as fruits and vegetables, are low in energy density. this study will examine whether there are increased benefits for weight loss and weight maintenance when the ad libitum consumption of water-rich foods is added to a reduced-fat diet, thus making it even lower in energy density. comparisons: reduced-energy-dense diet and reduced-fat diet

Eligibility criteria:
inclusion criteria: * healthy women * bmi (body mass index) 30 through 40 kg/m2 * normal blood pressure * ldl (low density lipoprotein)-cholesterol \< 90th percentile recommendations * triglycerides, fasting blood glucose, and all other blood values within normal ranges * able to participate in low to moderate physical activity. exclusion criteria: * heart disease * diabetes - type i or ii * high blood pressure * renal or kidney disease * gastrointestinal disease * blood clotting disorder * liver disease or cirrhosis * any oral steroids * gout (requiring treatment) * anemia * lung disease * cancer within the last 5 years * thyroid disease

Keywords: reduced-energy-density diet fat-restricted diet fruit vegetables ad libitum intake weight loss obesity
oxalobacter formigenes colonization and urinary oxalate excretion

Conditions: Calcium Oxalate Urolithiasis

Summary: the purpose of this research study is to assess the efficacy of ingesting a small amount of the harmless bacterium oxalobacter formigenes in establishing residence in the guts of healthy participants and to determine whether this influences the oxalate passed in urine.

adults that are not colonized with o. formigenes, have no history of stone disease, and are in good health as judged by their medical history and a complete metabolic profile of their serum, will be recruited from within the greater birmingham area. participants not colonized with o. formigenes will consume a controlled diet containing moderately high levels of oxalate (210-240 mg per day), and low levels of calcium (500 - 700 mg per day) and collect 24-hour urines to measure oxalate excretion. following completion of urine collections, participants will ingest live o.formigenes and one week later stool will be provided to test for colonization with o.formigenes. participants that are successfully colonized with o.formigenes will then repeat 24 hour urine collections on the same high oxalate, low calcium diet. controlled diets will be prepared in the metabolic kitchen of the uab clinical research unit (cru). sustainability of colonization will be determined over time. loss of colonization will be confirmed by having the subject consume an oxalate-rich meal with subsequent testing for o. formigenes.

Eligibility criteria:
inclusion criteria: * good health as judged from a medical history and reported medications * not colonized with o. formigenes exclusion criteria: * history of any hepatic, renal, bowel or endocrine disease or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results * colonized with o. formigenes * abnormal urine chemistries or blood metabolic profiles

Keywords: oxalobacter formigenes oxalate kidney stones
treatment study for problematic gaming and gambling

Conditions: Pathological Gambling; Internet Gaming Disorder

Summary: the aim of the study is twofold: 1) to evaluate an relaps prevention(rp) treatment for problematic gaming (pg) and internet gaming disorder (igd) patients recruited from child and youth psychiatry (cap) clinics and 2) to test whether the quality of parent-child relationships plays role in the effect of rp treatment and vice versa - whether the rp treatment has a spillover effect on the quality of parent-child relationships.

this study is a two-arm, parallel-group, single-blind, early-stage randomized clinical trial (rct) with embedded qualitative components. participants will be randomized in a 1:1 ratio to either intervention or control, with a total of 162 participants (81+81) in the trial. the primary outcomes are measures of gaming and gambling behavior pre- and post-intervention, and the secondary outcomes include child ratings of parent-child communication, including parental knowledge, control and solicitousness about child gaming, as well as child disclosure and secrecy related to gaming. preliminary analyses will be conducted with regression analyses, paired sample t-tests and anovas and performed in mplus. in addition to the rct, the study will be supplemented with a qualitative component with semi-structured individual interviews to capture participants' and clinicians' experiences of the treatment, as well as attitudes about parent-child relationships and parenting needs in carers whose children completed the rp treatment. the qualitative data will be analyzed with thematic analysis.

Eligibility criteria:
inclusion criteria * age 12-18 * over cut-off on gasa * over cut-off on clip exclusion criteria * not being able to speak swedish

Keywords: gaming gambling adolescent children
effect of vergence exercises for patients with convergence insufficiency after concussion.

Conditions: Concussion, Mild; Convergence Insufficiency

Summary: a large proportion of concussion patients with long-term consequences of concussion experience visually related symptoms such as headache, blurred vision, double vision, and fatigue. these patients often have difficulties coordinating the movement of the two eyes (convergence insufficiency) which is essential for single and clear vision to be obtained and is hence a likely explanation for the symptoms. 100 patients with long-term symptoms of concussion and convergence insufficiency will be offered either exercises or placebo treatment the evaluate the effect of exercises aimed at improving coordination between the two eyes. the study will provide data to support clinicians in deciding whether to use exercises or not as a treatment of symptoms for patients with convergence insufficiency as a long-term consequence of concussion.


Eligibility criteria:
inclusion criteria: * concussion at least 3 month ago * convergence insufficiency which has not been diagnosed prior to the concussion exclusion criteria: * patient who are unable to fulfill baseline examination * manifest or paralytic strabismus * self-reported eye disease
covered vs uncovered metal stents for palliative biliary decompression in inoperable malignant distal bile duct obstruction

Conditions: Distal Bile Duct Obstruction

Summary: the purpose of this study is to compare the rate of long-term stent failure, defined as need for repeat biliary intervention following placement of c-sems vs u-sems for palliation of inoperable malignant distal bile duct obstruction.


Eligibility criteria:
inclusion criteria: * distal bile obstruction referred for ercp with intended palliative metal stent placement for palliation of jaundice * 18 years of age or older * serum bilirubin \> 2mg/dl exclusion criteria: * prior endoscopic or percutaneous biliary drainage * post-surgical anatomy * primary site of biliary obstruction involving the common hepatic duct or hilum * tumor involving gastric outlet, duodenum, or ampulla either precluding endoscopic access to the papilla or otherwise preventing endoscopic biliary cannulation

Keywords: pancreatic cancer cholangiocarcinoma metastatic malignancy jaundice